Five Reasons The Hub-And-Spoke Model Is Gaining Traction In Biotech

By Willie Xiang and Tim Lu, M.D., Ph.D.

For decades, biotech companies were largely built around a familiar formula: one company, one lead asset, one therapeutic bet.

That model produced important medicines, but it also created structural limitations. Companies often rebuilt discovery infrastructure from scratch for each program, operated with limited flexibility across therapeutic areas, and tied enterprise value heavily to single binary outcomes.

Today, more biotech companies are moving toward a different organizational framework: the hub-and-spoke model.

The reason is increasingly clear. Modern disease biology is becoming more complex, while advances in artificial intelligence, protein engineering, synthetic biology, and computational drug design are making platform-based therapeutic development more scalable and modular than ever before.

Companies such as Roivant Sciences and BridgeBio Pharma helped pioneer elements of this approach. Roivant built a centralized parent company structure with individual “Vants” operating as focused subsidiaries around specific therapeutic programs. BridgeBio developed a model centered on multiple disease-focused affiliates supported by shared operational and strategic infrastructure. More recently, platform-centric biotech companies have increasingly adopted modular portfolio structures designed to repeatedly generate and advance therapeutic assets across multiple disease areas.

The model is gaining momentum because it addresses several of the industry’s biggest challenges simultaneously:

1. It Better Reflects The Complexity Of Modern Biology

Many of today’s largest therapeutic opportunities, including obesity, cardiometabolic disease, autoimmune disorders, and solid tumors are not driven by single pathways. They involve highly interconnected biological systems that often require multifaceted therapeutic approaches.

This challenge is becoming increasingly visible across medicine.

In obesity and cardiometabolic disease, for example, the market is rapidly evolving beyond weight loss alone toward broader management of systemic and organ-specific complications. In oncology, even advanced T-cell engager therapies continue to face limitations related to immune exhaustion, suppressive tumor microenvironments, and cold tumors. Autoimmune therapies similarly struggle with pathway redundancy, limited response durability, and systemic immunosuppression.

These realities are driving greater interest in multifunctional therapeutic architectures capable of modulating multiple biological mechanisms simultaneously.

At Protuoso Bio, this philosophy is reflected in MUXBODIES™, recombinant fusion proteins engineered to combine multiple signaling molecules, agonists, antagonists, masking systems, localization technologies, and PK/PD modulators into a single therapeutic construct.

The hub-and-spoke structure enables companies to systematically apply these platform capabilities across multiple disease categories rather than limiting them to a single asset.

2. It Creates A Compounding Innovation Engine

One of the most important advantages of the model is that scientific learning compounds over time.

Traditional biotech companies often operate in silos where discoveries remain program-specific. In contrast, hub-and-spoke organizations continuously strengthen the underlying platform with each iteration.

At Protuoso, the centralized hub is PROTUCORE™, an indication-agnostic protein engineering engine integrating computational protein design, synthetic biology, directed evolution systems, AI-driven optimization, and modular protein assembly.

Every improvement in manufacturability, linker optimization, translational pharmacology, computational design, or AI-guided engineering can accelerate future programs across the broader organization. The result is a continuously improving therapeutic generation system.

3. It Improves Capital Efficiency

Biotech remains one of the most infrastructure-intensive industries globally.

Building separate discovery engines, AI systems, translational workflows, manufacturing expertise, and engineering capabilities for every therapeutic program creates enormous duplication across the ecosystem.

The hub-and-spoke model centralizes these capabilities at the platform level while allowing multiple therapeutic programs to leverage the same infrastructure simultaneously. This can significantly improve operational efficiency while accelerating therapeutic iteration cycles.

It also creates more flexibility around how assets are financed and developed. Rather than forcing every program through the same corporate structure, individual spokes can pursue independent funding strategies, partnerships, or transactions while still benefiting from shared platform capabilities.

4. It Creates Multiple Independent Value-Creation Pathways

One of the reasons investors increasingly gravitate toward hub-and-spoke companies is that the structure naturally creates optionality. Different spoke programs can mature independently and pursue distinct strategic outcomes.

Some may become acquisition targets. Others may pursue IPOs or strategic partnerships. Meanwhile, the platform hub itself continues generating additional assets and enterprise value over time.

The biotech industry has already seen examples of this play out successfully. BridgeBio built significant value through its portfolio structure and platform-driven development approach. Roivant demonstrated how centralized infrastructure could support multiple therapeutic subsidiaries. Transactions such as AstraZeneca’s acquisition of CinCor and public financings such as Apogee Therapeutics’ IPO illustrate how focused asset programs can independently create substantial value within broader platform ecosystems.

This diversification of value creation may become increasingly important in today’s financing environment.

5. It Aligns With The Future Of Platform-Driven Biotech

The broader industry is increasingly moving toward programmable biology.

Artificial intelligence is accelerating molecular design. Synthetic biology is enabling modular therapeutic engineering. Protein engineering systems are becoming increasingly scalable and repeatable. Multifunctional therapeutics are beginning to address diseases previously considered too biologically complex for conventional approaches.

As this transition continues, the industry’s competitive advantage may shift away from ownership of a single molecule and toward ownership of systems capable of repeatedly generating differentiated medicines across multiple therapeutic areas.

In many ways, biotechnology is beginning to resemble other infrastructure-driven industries where centralized innovation engines power multiple downstream products.

The companies most likely to define the next generation of biotech may not simply be those with the best asset. They may be those capable of repeatedly creating new assets through scalable scientific infrastructure.

That is why the hub-and-spoke model is gaining momentum across biotech. It is designed not simply to build a single therapy, but to create a repeatable engine for therapeutic innovation, one capable of generating multiple differentiated medicines, accelerating development across programs, and compounding scientific and operational learning over time.

About The Authors:

Willie Xiang is the Cofounder, President, and Chief Operating Officer at Protuoso Biosciences.  

Tim Lu, M.D., Ph.D.is the Cofounder and Chairman at Protuoso Biosciences.